Nitin Abrol
Transplant Surgery · Oklahoma City, OKNPI 1134647183
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 55 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Veloxis Pharmaceuticals, Inc. at 37.8% of the total. Reporting peaked in 2022 at $521 and has fallen 91.4% since, to $45 in 2025.
Across 55 payments — averaging $19.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Veloxis Pharmaceuticals, Inc.$412
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$335
- Gilead$209
- AstraZeneca$62
- Intercept Pharmaceuticals, Inc.$43
- Abbott$15
- plus $14 from 1 others
What the payments were for
- Food & beverage$1,090100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Veloxis Pharmaceuticals, Inc. | 10 | $412 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 22 | $335 |
| Gilead | 15 | $209 |
| AstraZeneca | 3 | $62 |
| Intercept Pharmaceuticals, Inc. | 3 | $43 |
| Abbott | 1 | $15 |
| Medtronic | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Envarsus$206
How this compares
Too few transplant surgery providers in Oklahomato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other transplant surgery in Oklahoma City
- Yi HuangOklahoma City$16K
- Shinichiro YokotaOklahoma City$4K
- Maheswaran PitchaimuthuOklahoma City$3K
- Vivek KohliOklahoma City$3K
- Alan HawxbyOklahoma City$2K
- John DuffyOklahoma City$1K
- Anthony SebastianOklahoma City$1K
- Shi-Feng LiOklahoma City$448
- Ye YongOklahoma City$287
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.